6 November 2014For those who qualify as “Sophisticated Investor” status for the current capital-raising round, here is the latest information titled “Novogen – An Investment Opportunity”. The first two pages relate solely to those who qualify for this capital-raising. The other three pages however will be of interest to ALL Novogen shareholders. You can find the link to this document at…Latest Investor Update. HERE>Or just go to the homepage and click “Latest Investor Update” This short document includes details of two main drugs. Cantrixil and its use in Ovarian Cancer plus other indications… and Trilexium, in connection with primary brain cancer in both adults and children. Here are a couple of extracts that you may not have seen before… “In an animal model of recurrent ovarian cancer (post-Taxol treatment), Cantrixil monotherapy has proved to be 100% effective in eradicating the tumor.” “In an animal model of primary ovarian cancer, Cantrixil in combination with carboplatin is 100% successful in preventing tumor recurrence.” “Trilexium is the first drug to kill a library of GBM stem cells, providing hope that long-term remission is possible.The ability of Trilexium to kill a broad range of cancer types, suggests that it would be equally effective against secondary tumors in the brain as against primary brain tumors.”
[/table][/table][/table][/table]
NRT Price at posting:
12.0¢ Sentiment: Hold Disclosure: Held
